Dimension Therapeutics to Present at the Cowen and Company 35th Annual Health Care Conference

Cowen Health Care Conference 2015

CAMBRIDGE, Mass.--()--Dimension Therapeutics, Inc. (“Dimension” or the “Company”), a rare disease company with a world-class development team advancing novel, liver-directed treatments for diverse genetic disorders based upon an industry-leading AAV gene therapy platform, today announced that Annalisa Jenkins, MBBS, MRCP, President and Chief Executive Officer, will present a corporate overview at the Cowen and Company 35th Annual Health Care Conference on Monday, March 2, 2015 at 8:30 a.m. Eastern Time. The conference will be held at The Boston Marriott Copley Place Hotel in Boston, MA.

About Dimension Therapeutics

Dimension Therapeutics, Inc. is a rare disease company focused on developing novel treatments for devastating disorders associated with the liver. Dimension’s gene therapy pipeline is based on an industry-leading, extensively validated adeno-associated virus (AAV) platform. The company is advancing multiple programs toward clinical development, including: a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple best-in-class AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases. In June 2014 the company announced a Series A financing with participation by leading investors Fidelity Biosciences and OrbiMed. For more information, please visit www.dimensiontx.com.

Contacts

Burns McClellan, on behalf of Dimension Therapeutics
Nancy Yu, 212-213-0006
nyu@burnsmc.com